Join to View Full Profile
UCI Medical Center101 The City Drive SouthOrange, CA 92868
Phone+1 714-456-8978
Dr. Demetriou is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of TorontoNeurology Residency, 1996 - 2001
University of Toronto Faculty of MedicineClass of 1996
Certifications & Licensure
CA State Medical License 2001 - 2027
Royal College of Physicians and Surgeons of Canada Neurology
Publications & Presentations
PubMed
- 1 citationsN-Glycan Branching Regulates BTLA Opposite to PD-1 to Limit T Cell Hyperactivity Induced by Branching Deficiency.Haik Mkhikian, Raymond W Zhou, Hayk Saryan, Christofer Daniel Sánchez, Aswath Balakrishnan
Journal of Immunology. 2024-11-01 - 1 citationsThe Cancer Moonshot Immuno-Oncology Translational Network at 5: accelerating cancer immunotherapies.Ananth Annapragada, Andrew G Sikora, Himangi Marathe, Song Liu, Michael Demetriou
Journal of the National Cancer Institute. 2023-11-08 - 8 citationsN-acetylglucosamine inhibits inflammation and neurodegeneration markers in multiple sclerosis: a mechanistic trial.Michael Sy, Barbara L Newton, Judy Pawling, Ken L Hayama, Andres Cordon
Journal of Neuroinflammation. 2023-09-13
Press Mentions
New COVID-19 Vaccine Pod for Children Opens in BohemiaNovember 6th, 2021- Low Levels of a Sugar Metabolite Associated with Progressive Disability and Neurodegeneration in Multiple SclerosisMay 16th, 2021
- Simple Sugar Could Be a New Biomarker for Severe Multiple SclerosisMay 13th, 2021
- Join now to see all
Grant Support
- Extended half-life GlyTR1 combined with checkpoint blockade for Cancer ImmunotherapyGLYTR THERAPEUTICS, INC.2023–2026
- Extended half-life GlyTR1 combined with checkpoint blockade for Cancer ImmunotherapyGLYTR THERAPEUTICS, INC.2023–2026
- Extended half-life GlyTR1 combined with checkpoint blockade for Cancer ImmunotherapyGLYTR THERAPEUTICS, INC.2023–2026
- Institutional Career Development CoreUNIVERSITY OF CALIFORNIA-IRVINE2015–2025
- Regulation of B cell function in demyelinating disease by N-glycan branchingUNIVERSITY OF CALIFORNIA-IRVINE2019–2024
- T Cell Regulation By N-GlycosylationNational Institute Of Allergy And Infectious Diseases2010–2012
- Human Autoimmunity And Genetic Defects In N-GlycosylationNational Institute Of Allergy And Infectious Diseases2010–2012
- Multiple Sclerosis And Genetic Defects In N-GlycosylationNational Institute Of Allergy And Infectious Diseases2009
- Regulation Of T Cell Function And Autoimmunity By Mgat5National Institute Of Allergy And Infectious Diseases2003–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
